Cargando…

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer

Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T cells are primed to attack tumor cells. To elucidate the role of regio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inamori, Koji, Togashi, Yosuke, Fukuoka, Shota, Akagi, Kiwamu, Ogasawara, Kouetsu, Irie, Takuma, Motooka, Daisuke, Kobayashi, Yoichi, Sugiyama, Daisuke, Kojima, Motohiro, Shiiya, Norihiko, Nakamura, Shota, Maruyama, Shoichi, Suzuki, Yutaka, Ito, Masaaki, Nishikawa, Hiroyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262295/ https://www.ncbi.nlm.nih.gov/pubmed/33755600 http://dx.doi.org/10.1172/jci.insight.137365

Ejemplares similares

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
por: Song, Yunfeng, et al.
Publicado: (2021)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors
por: Leclerc, Julie, et al.
Publicado: (2021)

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
por: Zhou, Chengjing, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis
por: Fan, Shaoqing, et al.
Publicado: (2023)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
por: Kang, Yoon-Jung, et al.
Publicado: (2022)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
por: Tuninetti, Valentina, et al.
Publicado: (2023)

LDH‐A negatively regulates dMMR in colorectal cancer
por: Zhang, Yongjie, et al.
Publicado: (2021)

The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients
por: Wang, Jie, et al.
Publicado: (2021)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study
por: Li, Xiaofen, et al.
Publicado: (2022)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma
por: Wang, Zhenghang, et al.
Publicado: (2022)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

An unusual case of microsatellite instability–high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing
por: Han, Bogyeong, et al.
Publicado: (2022)

Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
por: Zhang, Xuan, et al.
Publicado: (2022)

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
por: Liao, Ying, et al.
Publicado: (2022)

Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
por: Yang, Renfang, et al.
Publicado: (2023)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Prognostic value of Lynch syndrome, BRAF(V600E) , and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
por: Zwart, Koen, et al.
Publicado: (2023)

Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021)

Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria
por: Sun, Ci-Yuan, et al.
Publicado: (2020)

Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters
por: Hashmi, Atif A, et al.
Publicado: (2023)

Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: A case report
por: Smith, Henry G., et al.
Publicado: (2023)

Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone
por: Ni, Kemin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uutc0m6dr1lj9jf1vgt9a8ns1m